net_left Phương Thức Thanh Toán
Phương Thức Thanh Toán

U.S. regulators defend requiring more data on monkeypox drug

By Julie Steenhuysen CHICAGO (Reuters) - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday defended their decision to require...
U.S. regulators defend requiring more data on monkeypox drug © Reuters. FILE PHOTO: Test tubes labelled "Monkeypox virus positive" are seen in this illustration taken May 23, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

By Julie Steenhuysen

CHICAGO (Reuters) - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday defended their decision to require human trial data to show that SIGA Technologies' experimental drug TPOXX is safe and effective to treat the virus.

U.S. agencies have been under pressure to ease access to the drug, which is being distributed by the U.S. Centers for Disease Control and Prevention (CDC) under a special "compassionate use" access that requires doctors to request it from the agency or their health department and enroll each patient in a study.

As of July 22, 223 people have been treated with the drug, compared with more than 6,000 known cases in the United States.

The FDA approved TPOXX in 2018 for smallpox in adults and children based on studies of animals infected with monkeypox and rabbitpox, as well as safety data in healthy people. It can only be sold to the U.S. Strategic National Stockpile.

Authors of the article in the New England Journal of Medicine from the Food and Drug Administration, the CDC and the National Institutes of Health (NIH) said the latter is planning a U.S.-based randomized clinical trial.

Data from that study will be used to determine whether the drug gains U.S. approval for monkeypox.

The drug, also known as tecovirimat, is approved for both smallpox and monkeypox in the UK and Europe. The European Union approved it under an "exceptional circumstances" pathway that allows for marketing approval when data cannot be obtained even after authorization.

Although TPOXX was only tested in healthy people, the European Medicines Agency said it expects side effects to be similar in infected people, and deemed the drug's benefits to be greater than its risks.

Dr. Jay Varma, director of the Cornell Center for Pandemic Prevention and Response who has advocated for broader access to the drug, said the FDA's standards ensure U.S. drugs are safe and set a high bar for the world, but in some circumstances, "those strict standards are harming us."

There were 1.7 million doses of the treatment in the U.S. Strategic National Stockpile at the start of the current outbreak in May.

On July 21, the CDC and the FDA began allowing doctors to prescribe the drug before the trial paperwork is completed, but still requires approval of a hospital's institutional review board for each dose.

"It's definitely better. It's still very burdensome," said Dr. Karen Krueger, an infectious disease expert at Northwestern (NASDAQ:NWE) Medicine in Chicago, who said there is additional paperwork after the patient visit and for several follow-up visits.

"It's doable but certainly a lot more challenging than how we normally prescribe drugs."

Neither the FDA nor the CDC immediately responded to a request for comment.

Northwestern has treated at least 20 monkeypox patients with TPOXX and will be one of the sites for the NIH trial.

To win approval, SIGA Chief Scientific Officer Dennis Hruby estimates it will likely take a 500-patient, placebo-controlled clinical trial in the United States.

If cases remain high, the trial could be fully enrolled within a few months. "It's not a terribly long trial," he said.

SIGA Chief Executive Phillip Gomez said the company is working to launch trials in the UK, Canada, the United States and Europe.

If the United States declares monkeypox a national emergency, Gomez said the drug could be granted an emergency use authorization. However, because the FDA has been "very clear" they want full, placebo-controlled trials, that could still take time, he said.

Hot Auto Trade Bot Phương Thức Thanh Toán
BROKERS ĐƯỢC CẤP PHÉP
net_home_top Ai VIF
10-08-2022 20:36:49 (UTC+7)

EUR/USD

1.0314

+0.0103 (+1.01%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (0)

Sell (9)

EUR/USD

1.0314

+0.0103 (+1.01%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (0)

Sell (9)

GBP/USD

1.2203

+0.0123 (+1.01%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (0)

Sell (9)

USD/JPY

133.07

-2.07 (-1.53%)

Summary

Sell

Moving Avg:

Buy (3)

Sell (9)

Indicators:

Buy (3)

Sell (5)

AUD/USD

0.7044

+0.0080 (+1.15%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (1)

Sell (7)

USD/CAD

1.2840

-0.0048 (-0.37%)

Summary

↑ Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (10)

Sell (0)

EUR/JPY

137.26

-0.73 (-0.53%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (9)

EUR/CHF

0.9724

-0.0013 (-0.13%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (2)

Sell (8)

Gold Futures

1,808.90

-3.40 (-0.19%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (10)

Silver Futures

20.515

+0.033 (+0.16%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (10)

Copper Futures

3.6338

+0.0483 (+1.35%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (0)

Sell (10)

Crude Oil WTI Futures

89.66

-0.84 (-0.93%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (9)

Brent Oil Futures

95.51

-0.80 (-0.83%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (10)

Natural Gas Futures

7.816

-0.017 (-0.22%)

Summary

↑ Sell

Moving Avg:

Buy (3)

Sell (9)

Indicators:

Buy (1)

Sell (6)

US Coffee C Futures

219.20

+6.45 (+3.03%)

Summary

Neutral

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (2)

Sell (4)

Euro Stoxx 50

3,744.05

+28.68 (+0.77%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (1)

Sell (7)

S&P 500

4,185.90

+63.43 (+1.54%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (5)

Sell (0)

DAX

13,657.35

+122.38 (+0.90%)

Summary

↑ Sell

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (0)

Sell (8)

FTSE 100

7,500.99

+12.84 (+0.17%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (8)

Hang Seng

19,610.84

-392.60 (-1.96%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (0)

US Small Cap 2000

1,943.65

+34.64 (+1.81%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (6)

Sell (0)

IBEX 35

8,351.25

+39.35 (+0.47%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (6)

Sell (2)

BASF SE NA O.N.

44.370

+0.375 (+0.85%)

Summary

↑ Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (8)

Sell (0)

Bayer AG NA

51.93

-0.23 (-0.44%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

Allianz SE VNA O.N.

179.14

+0.58 (+0.32%)

Summary

Neutral

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (4)

Sell (3)

Adidas AG

171.87

+2.87 (+1.70%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (0)

Deutsche Lufthansa AG

6.621

+0.048 (+0.73%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (9)

Sell (1)

Siemens AG Class N

108.50

+1.98 (+1.86%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (9)

Sell (0)

Deutsche Bank AG

8.788

+0.061 (+0.70%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (10)

Sell (0)

 EUR/USD1.0314↑ Sell
 GBP/USD1.2203↑ Sell
 USD/JPY133.07Sell
 AUD/USD0.7044Sell
 USD/CAD1.2840↑ Buy
 EUR/JPY137.26↑ Sell
 EUR/CHF0.9724↑ Sell
 Gold1,808.90↑ Sell
 Silver20.515↑ Sell
 Copper3.6338↑ Sell
 Crude Oil WTI89.66↑ Sell
 Brent Oil95.51↑ Sell
 Natural Gas7.816↑ Sell
 US Coffee C219.20Neutral
 Euro Stoxx 503,744.05↑ Sell
 S&P 5004,185.90↑ Buy
 DAX13,657.35↑ Sell
 FTSE 1007,500.99↑ Sell
 Hang Seng19,610.84↑ Buy
 Small Cap 20001,943.65↑ Buy
 IBEX 358,351.25↑ Buy
 BASF44.370↑ Buy
 Bayer51.93↑ Sell
 Allianz179.14Neutral
 Adidas171.87↑ Buy
 Lufthansa6.621↑ Buy
 Siemens AG108.50↑ Buy
 Deutsche Bank AG8.788↑ Buy
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank6,600/ 6,700
(-20/ -20) # 1,624
SJC HCM6,600/ 6,700
(-20/ -20) # 1,624
SJC Hanoi6,600/ 6,702
(-20/ -20) # 1,626
SJC Danang6,600/ 6,702
(-20/ -20) # 1,626
SJC Nhatrang6,600/ 6,702
(-20/ -20) # 1,626
SJC Cantho6,600/ 6,702
(-20/ -20) # 1,626
Cập nhật 10-08-2022 20:36:51
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$1,795.50+1.330.07%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩmVùng 1Vùng 2
RON 95-V26.28026.800
RON 95-III25.60026.110
E5 RON 92-II24.62025.110
DO 0.05S23.90024.370
DO 0,001S-V25.88026.390
Dầu hỏa 2-K24.53025.020
ↂ Giá dầu thô thế giới
WTI$89.28+0.550.61%
Brent$95.05+0.720.75%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD23.220,0023.530,00
EUR23.251,8824.554,01
GBP27.508,9128.682,08
JPY168,20178,07
KRW15,4618,84
Cập nhật lúc 18:51:10 10/08/2022
Xem bảng tỷ giá hối đoái
Phương Thức Thanh Toán